Last reviewed · How we verify
K301
K301 is a topical antimicrobial agent designed to treat fungal nail infections by inhibiting fungal growth and promoting nail healing.
K301 is a topical antimicrobial agent designed to treat fungal nail infections by inhibiting fungal growth and promoting nail healing. Used for Onychomycosis (fungal nail infection).
At a glance
| Generic name | K301 |
|---|---|
| Also known as | K40 |
| Sponsor | Moberg Pharma AB |
| Drug class | Antifungal agent |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
K301 is being developed by Moberg Pharma as a novel topical treatment for onychomycosis (fungal nail infection). The drug is formulated to penetrate the nail plate and deliver antifungal activity directly to infected tissue, with the goal of achieving higher efficacy and better tolerability compared to existing oral and topical antifungal treatments.
Approved indications
- Onychomycosis (fungal nail infection)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |